Description:
IC50 Value: N/A
Pyridostatin is a G-quadruplex-interacting drug which can promote growth arrest in human cancer cells by inducing replication- and transcription-dependent DNA damage.  Pyridostatin targets gene bodies containing clusters of sequences with a propensity for G-quadruplex formation.
in vitro: The increased mechanical stability of pyridostatin-bound G-quadruplex permits the determination of a dissociation constant K(d) of 490 ± 80 nM. The free-energy change of binding obtained from a Hess-like process provides an identical K(d) for pyridostatin and a K(d) of 42 ± 3 ?M for a weaker ligand RR110 [1]. Pyridostatin reduced SRC protein abundance and SRC-dependent cellular motility in human breast cancer cells, validating SRC as a target of this drug [2].
in vivo: N/A
Clinical trial: N/A